Bulletin
Investor Alert

April 16, 2020, 10:21 p.m. EDT

Ankylosing Spondylitis (Bekhterev's Disease) Market Insights with Key Company Profiles - Forecast to 2030

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AbbVie Inc. (ABBV)
  • X
    Amgen Inc. (AMGN)

or Cancel Already have a watchlist? Log In

Apr 16, 2020 Xherald -- Ankylosing Spondylitis (Bekhterev's Disease) Market Report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2030 .

Companies Covered:

AbbVie Inc. /zigman2/quotes/202428675/composite ABBV +0.38% , Adello Biologics LLC, Allergan plc , Alteogen Inc, Amgen Inc. /zigman2/quotes/209157011/composite AMGN -0.36% , Biocon Ltd, Celgene Corp, Coherus BioSciences, Inc. /zigman2/quotes/202304465/composite CHRS +12.75% , Galapagos NV /zigman2/quotes/205153380/composite GLPG +1.67% , Innovent Biologics Inc, Johnson & Johnson /zigman2/quotes/201724570/composite JNJ +0.71% , Merck KGaA /zigman2/quotes/206962101/composite MKKGY -0.48% , Momenta Pharmaceuticals, Inc. /zigman2/quotes/200094979/composite MNTA +1.82% , Novartis AG /zigman2/quotes/203243705/composite NVS -0.60% , Protalix BioTherapeutics, Inc. /zigman2/quotes/209722654/composite PLX -0.83% , Reliance Life Sciences Pvt Ltd, Sun Pharma Advanced Research Company Ltd, Xbrane Biopharma AB and others, request free sample for complete list of companies.

Get Sample Copy of Ankylosing Spondylitis (Bekhterev's Disease) Market Report -

https://www.marketinsightsreports.com/reports/01311810112/ankylosing-spondylitis-bekhterev-s-disease-market-insight-epidemiology-and-market-forecast-2030/inquiry/?Source=XH&mode=10

Ankylosing Spondylitis (Bekhterev's Disease) Product Profiles & Analysis

This part of the Ankylosing Spondylitis (Bekhterev's Disease) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, and mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Markets Covered
United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 2017-2030

Ankylosing Spondylitis (Bekhterev's Disease) Market Share by Therapies

This section focuses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2030 . The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Ankylosing Spondylitis (Bekhterev's Disease) emerging therapies.

Reimbursement Scenario in Ankylosing Spondylitis (Bekhterev's Disease)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Ankylosing Spondylitis (Bekhterev's Disease) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Ankylosing Spondylitis (Bekhterev's Disease) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Available discount@ ( Exclusive offer Upto 30%- Use code MIR 30):

/zigman2/quotes/202428675/composite
US : U.S.: NYSE
$ 92.92
+0.35 +0.38%
Volume: 5.23M
Aug. 7, 2020 4:02p
P/E Ratio
19.77
Dividend Yield
5.08%
Market Cap
$163.99 billion
Rev. per Employee
$1.09M
loading...
/zigman2/quotes/209157011/composite
US : U.S.: Nasdaq
$ 240.69
-0.86 -0.36%
Volume: 1.35M
Aug. 7, 2020 4:00p
P/E Ratio
19.67
Dividend Yield
2.66%
Market Cap
$140.97 billion
Rev. per Employee
$1.11M
loading...
/zigman2/quotes/202304465/composite
US : U.S.: Nasdaq
$ 19.63
+2.22 +12.75%
Volume: 4.27M
Aug. 7, 2020 4:00p
P/E Ratio
8.63
Dividend Yield
N/A
Market Cap
$1.40 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/205153380/composite
US : U.S.: Nasdaq
$ 190.75
+3.13 +1.67%
Volume: 140,552
Aug. 7, 2020 4:00p
P/E Ratio
65.80
Dividend Yield
N/A
Market Cap
$12.41 billion
Rev. per Employee
$567,924
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 148.60
+1.05 +0.71%
Volume: 3.64M
Aug. 7, 2020 4:00p
P/E Ratio
26.12
Dividend Yield
2.72%
Market Cap
$391.24 billion
Rev. per Employee
$603,509
loading...
/zigman2/quotes/206962101/composite
US : U.S.: OTC
$ 26.72
-0.13 -0.48%
Volume: 17,602
Aug. 7, 2020 3:45p
P/E Ratio
32.91
Dividend Yield
0.73%
Market Cap
$58.20 billion
Rev. per Employee
$338,460
loading...
/zigman2/quotes/200094979/composite
US : U.S.: Nasdaq
$ 32.99
+0.59 +1.82%
Volume: 869,317
Aug. 7, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$3.88 billion
Rev. per Employee
$577,015
loading...
/zigman2/quotes/203243705/composite
US : U.S.: NYSE
$ 82.91
-0.50 -0.60%
Volume: 1.29M
Aug. 7, 2020 4:00p
P/E Ratio
26.38
Dividend Yield
2.42%
Market Cap
$182.38 billion
Rev. per Employee
$415,614
loading...
/zigman2/quotes/209722654/composite
US : U.S.: NYSE American
$ 3.59
-0.03 -0.83%
Volume: 65,524
Aug. 7, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$116.47 million
Rev. per Employee
$186,087
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.